BR9915701A - Composto, droga contendo um composto, e, uso de um composto - Google Patents

Composto, droga contendo um composto, e, uso de um composto

Info

Publication number: BR9915701A
Authority: BR; Brazil
Prior art keywords: compound; relates; compounds; drug containing; ring
Prior art date: 1998-11-27

Application number

BR9915701-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Wilfried Lubisch

Michael Kock

Thomas H Ger

Sabine Schult

Roland Grandel

Reinhold M Ller

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-27

Filing date

1999-11-23

Publication date

2001-08-14

1999-04-12 Priority claimed from DE1999116460 external-priority patent/DE19916460B4/de

1999-11-23 Application filed by Basf Ag filed Critical Basf Ag

2001-08-14 Publication of BR9915701A publication Critical patent/BR9915701A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BR9915701-2A 1998-11-27 1999-11-23 Composto, droga contendo um composto, e, uso de um composto BR9915701A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19854933		1998-11-27
DE1999116460 DE19916460B4 (de)	1999-04-12	1999-04-12	Substituierte Benzimidazole, deren Herstellung und Anwendung
PCT/EP1999/009004 WO2000032579A1 (de)	1998-11-27	1999-11-23	Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Publications (1)

Publication Number	Publication Date
BR9915701A true BR9915701A (pt)	2001-08-14

Family

ID=26050434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9915701-2A BR9915701A (pt)	1998-11-27	1999-11-23	Composto, droga contendo um composto, e, uso de um composto

Country Status (32)

Country	Link
US (2)	US6448271B1 (zh)
EP (1)	EP1133477B1 (zh)
JP (1)	JP3432800B2 (zh)
KR (1)	KR100417779B1 (zh)
CN (1)	CN1184208C (zh)
AR (1)	AR021400A1 (zh)
AT (1)	ATE259789T1 (zh)
AU (1)	AU764216B2 (zh)
BG (1)	BG65047B1 (zh)
BR (1)	BR9915701A (zh)
CA (1)	CA2352554C (zh)
CZ (1)	CZ300148B6 (zh)
DE (1)	DE59908600D1 (zh)
DK (1)	DK1133477T3 (zh)
ES (1)	ES2216625T3 (zh)
HK (1)	HK1042084B (zh)
HR (1)	HRP20010484B1 (zh)
HU (1)	HUP0200749A3 (zh)
IL (2)	IL143303A0 (zh)
MY (1)	MY128488A (zh)
NO (1)	NO20012570L (zh)
NZ (1)	NZ511825A (zh)
PL (1)	PL196367B1 (zh)
PT (1)	PT1133477E (zh)
RU (1)	RU2001117757A (zh)
SI (1)	SI1133477T1 (zh)
SK (1)	SK285529B6 (zh)
TR (1)	TR200101498T2 (zh)
TW (1)	TWI247741B (zh)
UA (1)	UA61158C2 (zh)
WO (1)	WO2000032579A1 (zh)
ZA (1)	ZA200104118B (zh)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
DE59911249D1 (de)	1998-11-03	2005-01-13	Abbott Gmbh & Co Kg	Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DE19920936A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) *	1999-09-17	2001-03-29	Yamanouchi Pharmaceutical Co., Ltd.	Dérivés de benzimidazole
ES2233671T3 (es) *	2000-08-08	2005-06-16	Sanofi-Aventis	Derivados de benzimidazol, su preparacion y aplicacion en terapeutica.
FR2812878B1 (fr) *	2000-08-08	2002-10-11	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) *	2000-11-23	2003-01-31	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr)	2000-11-23	2003-05-09	Sanofi Synthelabo	Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2002068407A1 (en) *	2001-02-28	2002-09-06	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole compound
JP2004528304A (ja)	2001-03-12	2004-09-16	アバニール・ファーマシューティカルズ	ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
US20040242635A1 (en) *	2001-03-30	2004-12-02	Painter Rachel J.	Encapsulated dyes in cosmetic compositions
WO2003007959A1 (en) *	2001-07-16	2003-01-30	Fujisawa Pharmaceutical Co., Ltd.	Quinoxaline derivatives which have parp inhibitory action
DE50310378D1 (de)	2002-07-26	2008-10-02	Basf Plant Science Gmbh	Neue selektionsverfahren
AU2003252314A1 (en) *	2002-08-09	2004-02-25	Kyorin Pharmaceutical Co., Ltd.	4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof
AU2003270426A1 (en)	2002-09-12	2004-04-30	Avanir Pharmaceuticals	PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en)	2002-09-12	2007-03-21	Avanir Pharmaceuticals	Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
MXPA05003948A (es) *	2002-10-17	2005-06-17	Amgen Inc	Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
HU0301154D0 (en) *	2003-04-28	2003-07-28	Hideg Kalman Dr	Pharmaceutical composition
WO2006094976A2 (en)	2005-03-08	2006-09-14	Basf Plant Science Gmbh	Expression enhancing intron sequences
US20060223849A1 (en) *	2005-03-14	2006-10-05	Mjalli Adnan M	Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
AU2012200399B2 (en) *	2005-04-11	2013-07-11	Abbvie Ireland Unlimited Company	1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2006110683A1 (en) *	2005-04-11	2006-10-19	Abbott Laboratories	2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) *	2005-04-11	2012-11-01	Abbott Lab	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
BRPI0611814A2 (pt) *	2005-06-10	2008-12-09	Bipar Sciences Inc	moduladores parp e tratamento de cÂnceres
US7825543B2 (en)	2005-07-12	2010-11-02	Massachusetts Institute Of Technology	Wireless energy transfer
KR101136889B1 (ko)	2005-07-12	2012-04-20	메사추세츠 인스티튜트 오브 테크놀로지	무선 비-방사성 에너지 전달
NZ587586A (en) *	2005-07-18	2012-04-27	Bipar Sciences Inc	Treatment of cancer
EP1957477B1 (en)	2005-09-29	2011-12-07	Abbott Laboratories	1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
EP1779849A1 (en) *	2005-10-28	2007-05-02	Nikem Research S.R.L.	V-ATPase inhibitors for the treatment of septic shock
CA2628461C (en)	2005-11-15	2013-09-24	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20080280867A1 (en) *	2006-01-17	2008-11-13	Abbott Laboratories	Combination therapy with parp inhibitors
US20080146638A1 (en) *	2006-01-17	2008-06-19	Abbott Laboratories	Combination therapy with parp inhibitors
CN101370497B (zh) *	2006-01-17	2010-11-17	雅培制药有限公司	包含parp抑制剂和细胞毒性剂的联合产品及用途
US20090029966A1 (en) *	2006-01-17	2009-01-29	Abbott Laboratories	Combination therapy with parp inhibitors
US20080293795A1 (en) *	2006-01-17	2008-11-27	Abbott Laboratories	Combination therapy with parp inhibitors
AU2007232297B2 (en) *	2006-04-03	2012-09-20	Msd Italia S.R.L.	Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2012780B1 (en) *	2006-05-02	2012-04-11	Abbott Laboratories	Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20070292883A1 (en) *	2006-06-12	2007-12-20	Ossovskaya Valeria S	Method of treating diseases with PARP inhibitors
AU2007292387A1 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Treatment of cancer
EP2061479A4 (en) *	2006-09-05	2010-08-04	Bipar Sciences Inc	FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
EP2805945B1 (en)	2007-01-10	2019-04-03	MSD Italia S.r.l.	Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
JP5469595B2 (ja)	2007-04-13	2014-04-16	ミレニアムファーマシューティカルズ，インコーポレイテッド	第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法
US8067613B2 (en) *	2007-07-16	2011-11-29	Abbott Laboratories	Benzimidazole poly(ADP ribose)polymerase inhibitors
US8138168B1 (en) *	2007-09-26	2012-03-20	Takeda Pharmaceutical Company Limited	Renin inhibitors
CA2696423A1 (en) *	2007-10-12	2009-04-16	Guidong Zhu	2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
US20090123419A1 (en) *	2007-11-12	2009-05-14	Bipar Sciences	Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
CA2705537A1 (en) *	2007-11-12	2009-05-22	Bipar Sciences, Inc.	Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
ES2548131T3 (es) *	2008-01-08	2015-10-14	Merck Sharp & Dohme Limited	Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
CA2713156A1 (en) *	2008-02-04	2009-08-13	Bipar Sciences, Inc.	Methods of diagnosing and treating parp-mediated diseases
JP2011511078A (ja) *	2008-02-06	2011-04-07	レアドトヘラペウトイクス，インコーポレーテッド	ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
WO2010083199A1 (en) *	2009-01-19	2010-07-22	Abbott Laboratories	Benzthiazole inhibitors of poly(adp-ribose)polymerase
US8513433B2 (en)	2009-07-02	2013-08-20	Angion Biomedica Corp.	Small molecule inhibitors of PARP activity
AU2010325549B2 (en)	2009-11-27	2017-04-20	Basf Plant Science Company Gmbh	Optimized endonucleases and uses thereof
EP2504429B1 (en)	2009-11-27	2016-04-20	BASF Plant Science Company GmbH	Chimeric endonucleases and uses thereof
CN102762726A (zh)	2009-11-27	2012-10-31	巴斯夫植物科学有限公司	嵌合内切核酸酶及其用途
ES2523503T3 (es) *	2010-03-04	2014-11-26	Bayer Intellectual Property Gmbh	2-Amidobencimidazoles sustituidos con fluoroalquilo y su uso para el aumento de la tolerancia al estrés en plantas
US20140051737A1 (en) *	2011-05-10	2014-02-20	Universite Laval	Methods for the treatment and diagnostic of pulmonary arterial hypertension
WO2013014038A1 (en) *	2011-07-26	2013-01-31	Nerviano Medical Sciences S.R.L.	3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
EP2561759A1 (en)	2011-08-26	2013-02-27	Bayer Cropscience AG	Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh)	2011-11-30	2015-01-14	成都地奥制药集团有限公司	一种多聚(adp-核糖)聚合酶抑制剂
CN102617502A (zh) *	2012-03-19	2012-08-01	江苏先声药物研究有限公司	一类苯并噁唑衍生物及其医药应用
JP2015532650A (ja)	2012-09-05	2015-11-12	バイエル・クロップサイエンス・アクチェンゲゼルシャフト	非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用
GB201223265D0 (en) *	2012-12-21	2013-02-06	Selvita Sa	Novel benzimidazole derivatives as kinase inhibitors
CN104230897B (zh) *	2013-06-17	2016-07-06	上海汇伦生命科技有限公司	苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230898B (zh) *	2013-06-17	2016-06-29	上海汇伦生命科技有限公司	苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN103396405A (zh) *	2013-08-21	2013-11-20	中国药科大学	具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN103483322A (zh) *	2013-08-21	2014-01-01	中国药科大学	5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途
WO2018022851A1 (en)	2016-07-28	2018-02-01	Mitobridge, Inc.	Methods of treating acute kidney injury
US11384081B2 (en)	2016-09-20	2022-07-12	Centre Leon Berard	Benzoimidazole derivatives as anticancer agents
RU2019114863A (ru)	2016-11-02	2020-12-03	Иммуноджен, Инк.	Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CN109232540A (zh) *	2018-06-15	2019-01-18	深圳市坤健创新药物研究院	一种取代苯并咪唑衍生物及应用
CN108997320A (zh) *	2018-08-30	2018-12-14	深圳市坤健创新药物研究院	一种含氟取代苯并咪唑衍生物及应用
CN113330007A (zh)	2018-10-03	2021-08-31	特沙诺有限公司	尼拉帕利游离碱的晶体形式

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1354554U (zh)
US4093726A (en)	1976-12-02	1978-06-06	Abbott Laboratories	N-(2-benzimidazolyl)-piperazines
TR199800127T1 (xx)	1995-08-02	1998-04-21	Newcastle University Ventures Limited	Benzimidazol bile�ikleri.
US6001866A (en)	1995-10-05	1999-12-14	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5972980A (en)	1995-10-05	1999-10-26	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5830905A (en)	1996-03-29	1998-11-03	Viropharma Incorporated	Compounds, compositions and methods for treatment of hepatitis C
ES2124167B1 (es)	1996-06-04	1999-09-16	Espanola Prod Quimicos	Nuevos derivados del bencimidazol con actividad antihistaminica.
GB9702701D0 (en)	1997-02-01	1997-04-02	Univ Newcastle Ventures Ltd	Quinazolinone compounds
US6303627B1 (en)	1998-06-19	2001-10-16	Eli Lilly And Company	Inhibitors of serotonin reuptake

1999
- 1999-11-23 ES ES99964497T patent/ES2216625T3/es not_active Expired - Lifetime
- 1999-11-23 SK SK714-2001A patent/SK285529B6/sk not_active IP Right Cessation
- 1999-11-23 DK DK99964497T patent/DK1133477T3/da active
- 1999-11-23 HK HK02103400.6A patent/HK1042084B/zh not_active IP Right Cessation
- 1999-11-23 US US09/856,686 patent/US6448271B1/en not_active Ceased
- 1999-11-23 UA UA2001064494A patent/UA61158C2/uk unknown
- 1999-11-23 AU AU30343/00A patent/AU764216B2/en not_active Ceased
- 1999-11-23 PT PT99964497T patent/PT1133477E/pt unknown
- 1999-11-23 WO PCT/EP1999/009004 patent/WO2000032579A1/de not_active Ceased
- 1999-11-23 HU HU0200749A patent/HUP0200749A3/hu unknown
- 1999-11-23 CA CA002352554A patent/CA2352554C/en not_active Expired - Fee Related
- 1999-11-23 AT AT99964497T patent/ATE259789T1/de active
- 1999-11-23 JP JP2000585221A patent/JP3432800B2/ja not_active Expired - Fee Related
- 1999-11-23 EP EP99964497A patent/EP1133477B1/de not_active Expired - Lifetime
- 1999-11-23 RU RU2001117757/04A patent/RU2001117757A/ru unknown
- 1999-11-23 IL IL14330399A patent/IL143303A0/xx active IP Right Grant
- 1999-11-23 CZ CZ20011855A patent/CZ300148B6/cs not_active IP Right Cessation
- 1999-11-23 PL PL347884A patent/PL196367B1/pl unknown
- 1999-11-23 NZ NZ511825A patent/NZ511825A/en not_active IP Right Cessation
- 1999-11-23 TR TR2001/01498T patent/TR200101498T2/xx unknown
- 1999-11-23 DE DE59908600T patent/DE59908600D1/de not_active Expired - Lifetime
- 1999-11-23 BR BR9915701-2A patent/BR9915701A/pt not_active IP Right Cessation
- 1999-11-23 SI SI9930543T patent/SI1133477T1/xx unknown
- 1999-11-23 CN CNB998151130A patent/CN1184208C/zh not_active Expired - Fee Related
- 1999-11-23 KR KR10-2001-7006611A patent/KR100417779B1/ko not_active Expired - Fee Related
- 1999-11-23 HR HR20010484A patent/HRP20010484B1/xx not_active IP Right Cessation
- 1999-11-23 US US10/935,683 patent/USRE39608E1/en not_active Expired - Lifetime
- 1999-11-25 AR ARP990106011A patent/AR021400A1/es unknown
- 1999-11-26 TW TW088120715A patent/TWI247741B/zh not_active IP Right Cessation
- 1999-11-27 MY MYPI99005192A patent/MY128488A/en unknown
2001
- 2001-05-21 ZA ZA200104118A patent/ZA200104118B/xx unknown
- 2001-05-22 IL IL143303A patent/IL143303A/en not_active IP Right Cessation
- 2001-05-25 NO NO20012570A patent/NO20012570L/no not_active Application Discontinuation
- 2001-06-13 BG BG105596A patent/BG65047B1/bg unknown

Also Published As

Publication number	Publication date
KR20010080596A (ko)	2001-08-22
HUP0200749A3 (en)	2003-03-28
BG65047B1 (bg)	2007-01-31
IL143303A (en)	2006-12-10
KR100417779B1 (ko)	2004-02-05
ES2216625T3 (es)	2004-10-16
CZ20011855A3 (cs)	2001-08-15
EP1133477B1 (de)	2004-02-18
DE59908600D1 (de)	2004-03-25
SK285529B6 (sk)	2007-03-01
AU3034300A (en)	2000-06-19
TR200101498T2 (tr)	2001-11-21
WO2000032579A1 (de)	2000-06-08
ZA200104118B (en)	2002-05-21
HRP20010484B1 (hr)	2010-08-31
TWI247741B (en)	2006-01-21
AR021400A1 (es)	2002-07-17
EP1133477A1 (de)	2001-09-19
CZ300148B6 (cs)	2009-02-25
US6448271B1 (en)	2002-09-10
CA2352554C (en)	2006-10-10
PL196367B1 (pl)	2007-12-31
RU2001117757A (ru)	2004-02-27
SI1133477T1 (en)	2004-06-30
PT1133477E (pt)	2004-06-30
DK1133477T3 (da)	2004-06-21
CA2352554A1 (en)	2000-06-08
AU764216B2 (en)	2003-08-14
HRP20010484A2 (en)	2003-04-30
NO20012570D0 (no)	2001-05-25
HK1042084B (zh)	2005-09-02
UA61158C2 (uk)	2003-11-17
HUP0200749A2 (en)	2002-08-28
JP3432800B2 (ja)	2003-08-04
BG105596A (en)	2002-02-28
NZ511825A (en)	2003-08-29
ATE259789T1 (de)	2004-03-15
HK1042084A1 (zh)	2002-08-02
SK7142001A3 (en)	2001-12-03
JP2002531442A (ja)	2002-09-24
CN1184208C (zh)	2005-01-12
USRE39608E1 (en)	2007-05-01
PL347884A1 (en)	2002-04-22
MY128488A (en)	2007-02-28
NO20012570L (no)	2001-07-13
CN1332731A (zh)	2002-01-23
IL143303A0 (en)	2002-04-21

Publication	Publication Date	Title
BR9915701A (pt)	2001-08-14	Composto, droga contendo um composto, e, uso de um composto
BR0316496A (pt)	2005-10-11	Quinolin-, isoquinolin-, e quinazolin-oxialquilamidas e seu emprego como fungicidas
PT939627E (pt)	2004-02-27	Pentafluorobenzenossulfonamidas e analogos
BR0115452A (pt)	2003-12-23	Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
TR200201505T2 (tr)	2003-01-21	Terapötik maddeler olarak pirazolopirimidinler
BR9911779A (pt)	2001-02-06	Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
PA8452201A1 (es)	2000-05-24	Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos.
ATE401314T1 (de)	2008-08-15	Benzodiazepin-derivate als gamma-secretase inhibitoren
BR0113146A (pt)	2003-06-24	Derivados de prolina e uso destes como drogas
EA200401056A1 (ru)	2005-04-28	Комбинация, содержащая производные тропана, полезные в терапии
BR9709427A (pt)	2000-01-11	Oxa ácidos e compostos relacionados para tratamento de condições da pele
BRPI0416692A (pt)	2007-01-30	inibidores heterocìclicos de mek e métodos de emprego destes
BR0007527A (pt)	2001-12-04	Fenilfenantridinas com atividade inibitória depde-iv
NZ330973A (en)	2000-03-27	Azolobenzazepine derivatives as neurologically active agents
ATE360631T1 (de)	2007-05-15	Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BR0312232A (pt)	2005-05-10	Inibidores de caspases e seus usos
MA29213B1 (fr)	2008-02-01	Quinolones a substitution macrolones - amino
BR0309748A (pt)	2005-02-15	Derivados de n-acil piperidina e composição compreendendo os mesmos
BR0311960A (pt)	2005-03-22	Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
BR0113583A (pt)	2003-07-15	2-guanidino-4-arilquinazolinas
PT1206444E (pt)	2004-04-30	Compostos que inibem a actividade da triptase
BR9916807A (pt)	2001-10-23	Antagonistas de 5ht1 para terapia antidepressiva
EA200100141A1 (ru)	2001-06-25	Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
EA200100140A1 (ru)	2001-06-25	Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
PA8471801A1 (es)	2000-09-29	Derivados de higromicina a

Legal Events

Date	Code	Title	Description
2007-09-04	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.
2011-12-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.